Live Breaking News & Updates on Serono Merck

Stay updated with breaking news from Serono merck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Checkpoint Inhibitors Clinical Trial Pipeline Insights | 180+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |

Checkpoint Inhibitors Clinical Trial Pipeline Insights | 180+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

Sandeep Joshi , Immuneonco Biopharma , Akeso Biopharma , Serono Merck , Lyvgen Biopharma , Mereo Biopharma , Theravance Biopharma , Eucure Biopharma , Bristol Myers Squibb , Innovent Biologics , Lepu Biopharma , Market Research , Boehringer Ingelheim , Canbas Co Ltd , Key Checkpoint Inhibitors Companies , Secarna Pharmaceuticals Gmbh Co , Seagen Inc , Phio Pharmaceuticals , Alpine Immune Sciences , Route Of Administration , Tracon Pharmaceuticals Inc , Key Companies , Bio Thera Solutions , Shanghai Henlius Biotech Inc , Healthcare Services , Enlivex Therapeutics Ltd ,

Monitoring ctDNA After Colorectal Cancer Surgery

Cell-free DNA concentration is significantly increased in the first 2 weeks after surgery but these higher levels do not seem to interfere with monitoring of circulating tumor DNA for prognostic purposes. ....

United States , Helsell Fetterman , Dustin Deming , Robins Kaplan , Serono Merck , Bristol Myers Squibb , Aadi Bioscience , University Of Wisconsin , Association Of Community Cancer Centers , Medscape Medical News , Community Cancer Centers , Istari Oncology , Taiho Oncology , Boston Biomedical , Isofol Medical , Seattle Genetics , Marcus Ventures , Revolution Medicines , Colorectal Cancer , Alignant Neoplasia , Colon Cancer , Alignant Colon Neoplasm , Adjuvant Chemotherapy , Adjuvant Therapy , Clinical Research , Clinical Trials ,

Can MS Be Stopped Early in its Tracks?

The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%. ....

United States , Santa Monica , University Of Texas Southwestern Medical Center , Noord Holland , Celgene Bristol Myers Squibb , Viela Bio , Barbara Giesser , Darin Okuda , Serono Merck , Pacific Neuroscience Institute In Santa Monica , Janssen Pharmaceuticals , Osmotica Pharmaceuticals , Research In Multiple Sclerosis , European Committee For Treatment , Texas Southwestern Medical Center , European Committee , Multiple Sclerosis , Medscape Medical News , Pacific Neuroscience Institute , Bristol Myers Squibb , Multiple Sclerosis Ms , Multiple Sclerosis , Ms Lesion , Ultiple Sclerosis Lesion , Multiple Sclerosis Imaging , S Imaging ,

The Changing Face of Multiple Sclerosis: Addressing the Demographic Shift Towards Elderly Patients

The Changing Face of Multiple Sclerosis: Addressing the Demographic Shift Towards Elderly Patients
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United States , Jennifer Frederick , Rosalyn Rosenthal , Sanofi Genzyme , Johnl Trotter , Genzyme Sanofi , Barbaraa Niedz , Bristol Myers Squibb , Patricia Melville , Ronalda Codario , Bianca Weinstock Guttman , Patriciak Coyle , Genentech Roche , Serono Merck , Janssen Johnson , Anneh Cross , Department Of Neurology , Accreditation Council For Pharmacy Education , Serono Inc , Stony Brook Ms Comprehensive Care Center , Ineligible Company , Program Number , Research Contractor , Jacobs School Of Medicine , Clinical Affairs , Accreditation Council For Continuing Medical Education ,

Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer

Share this article
Share this article
BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer. Reporting directly to the Chief Executive Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community.
Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team, said Syed Kazmi, Ph.D., President and Chief Executive Officer of Jubilant Therapeutics. His experience and leadership advancing novel targeted therapeutics will be integral as we execute our corporate vision. ....

United States , Luca Rastelli , Serono Merck , Syed Kazmi , Department Of Neuro , Prnewswire Jubilant Therapeutics Inc , Kleo Pharmaceuticals , University Of Geneva , American Brain Tumor Association , Md Anderson Cancer Center , Therapeutics Inc , Chief Scientific , Chief Executive Officer , Jubilant Therapeutics , Chief Scientific Officer , Vice President , Bioxcel Therapeutics , Boston Scientifics , Merck Serono , Anniversary Translational , Molecular Biology , Jubilant Therapeutics Inc , ஒன்றுபட்டது மாநிலங்களில் , செரோனோ மெர்க் , சையத் காஜ்மி , துறை ஆஃப் நரம்பியல் ,